1-(3-Fluorobenzyl)-1H-imidazole-2-carboxylic acid | 1439897-61-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3-Fluorobenzyl)-1H-imidazole-2-carboxylic acid
• 英文别名: 1-[(3-fluorophenyl)methyl]imidazole-2-carboxylic acid
• CAS: 1439897-61-6
• 化学式: C₁₁H₉FN₂O₂
• 分子量: 220.2
• InChiKey: AWCLWIBIPNQHCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Imidazole derivatives as factor Xa inhibitors
  申请人：AVENTIS PHARMA DEUTSCHLAND GMBH

  公开号：US20040171604A1

  公开（公告）日：2004-09-02

  This invention is directed to the compound of formula (I) which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as in inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

  本发明涉及一种化合物(I)，其可用于抑制Xa因子的活性。本发明还涉及含有该化合物的组合物、其制备过程、其用途，例如抑制凝血酶形成或用于治疗或预防患有与心血管疾病相关联的疾病状态的患者。
• IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1569927A2

  公开（公告）日：2005-09-07
• US7358268B2
  申请人：——

  公开号：US7358268B2

  公开（公告）日：2008-04-15
• [EN] IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS<br/>[FR] DERIVES DE L'IMIDAZOLE UTILISES COMME INHIBITEURS DU FACTEUR XA
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2004050636A2

  公开（公告）日：2004-06-17

  The present invention relates to compounds of the formula (I), wherein R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.